Alimera Sciences

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Its commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration and retinal vein occlusion.

Revenue(FY, 2016)

$34.3 M

Market capitalization(2018-04-23)

$74.7 M

Type

Public

Alpharetta, US

Founded

2003

Size (employees)

125 (est)

Website

alimerasciences.com

Alimera Sciences was founded in 2003 and is headquartered in Alpharetta, US

Report incorrect company information

Key People/Management at Alimera Sciences

Ken Greene

CSO

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs

Philip Ashman

SVP & European Managing Director

Rick Eiswirth

President & CFO

Dave Holland

SVP of Sales & Marketing

Report incorrect company information

Alimera Sciences Office Locations

Alimera Sciences has offices in Hampshire, Alpharetta, Berlin and Lisbon

Alpharetta, US (HQ)

6120 Windward Pkwy

Berlin, DE

21 Cicerostraße

Hampshire, GB

Wellesley Rd

Show all (4)

Report incorrect company information

Alimera Sciences Financials and Metrics

Alimera Sciences Financials

Alimera Sciences's revenue was reported to be $34.33 m in FY, 2016 which is a 53% increase from the previous period.

Summary

USD
Revenue (Q2, 2017)	10.4 m
Net income (Q2, 2017)	(2.8 m)
EBIT (Q2, 2017)	(1.4 m)
Market capitalization (23-Apr-2018)	74.7 m
Cash (30-Jun-2017)	26.9 m

Alimera Sciences's current market capitalization is $74.7 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	1.9 m	8.4 m	22.4 m	34.3 m
Revenue growth, %		350%	166%	53%
Cost of goods sold	1.9 m
Gross profit	9 k

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Revenue	758 k	2.1 m	2.2 m	2.4 m	3.9 m	5.8 m	6.9 m	5.8 m	9.6 m	8.3 m	6.6 m	10.4 m
Cost of goods sold	57 k	564 k	376 k
Gross profit	701 k	1.5 m	1.8 m
Gross profit Margin, %	92%	73%	83%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	12.6 m	76.7 m	31.1 m	31 m
Accounts Receivable	500 k	850 k	9.8 m	13.8 m
Inventories	3.5 m	3.2 m	2.7 m	446 k
Current Assets	18.6 m	83.3 m	45.2 m	47.4 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	23.1 m	41.3 m	42 m	61.4 m	61.3 m	48.1 m	39.3 m	23.9 m	16.6 m	33.9 m	26.7 m	26.9 m
Accounts Receivable	464 k	1.3 m	1 m	1.1 m	3.4 m	7.7 m	9.4 m	9.1 m	13.3 m	13.4 m	10.8 m	13.6 m
Inventories	3 m	1.2 m	1.4 m	1.7 m	2.1 m	1.6 m	1.7 m	1.4 m	1.2 m	913 k	802 k	1.1 m
Current Assets	30.1 m	46.5 m	47.5 m	67.3 m	70.3 m	61.1 m	53.4 m	37.2 m	34.7 m	51.6 m	40.5 m	44.3 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(46.2 m)	(35.9 m)	(30.6 m)	(33.2 m)
Depreciation and Amortization	138 k	659 k	2.6 m	2.8 m
Inventories	(1.4 m)	206 k	405 k	1 m
Accounts Payable	(259 k)	3 m	(487 k)	1.1 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Net Income	(31.5 m)	(20.8 m)	(19.6 m)	(26.7 m)	(9.8 m)	(18.4 m)	(19.9 m)	(11.1 m)	(18 m)	(27.2 m)	(6.7 m)	(9.5 m)
Depreciation and Amortization	101 k	36 k	69 k	151 k	558 k	1.2 m	1.9 m	689 k	1.4 m	2.1 m	666 k	1.3 m
Inventories	(2.2 m)	548 k	400 k	(9 k)	(455 k)	(16 k)	(88 k)	164 k	301 k	612 k	(361 k)	(719 k)
Accounts Payable	717 k	111 k	122 k	1.3 m	272 k	(1.2 m)	(1.4 m)	(1.5 m)	264 k	(2.1 m)	(1.1 m)	572 k